Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Lipocine stock
Learn how to easily invest in Lipocine stock.
Lipocine Inc is a biotechnology business based in the US. Lipocine shares (LPCN) are listed on the NASDAQ and all prices are listed in US Dollars. Lipocine employs 13 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Lipocine
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – LPCN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Lipocine stock price (NASDAQ: LPCN)Use our graph to track the performance of LPCN stocks over time.
Lipocine shares at a glance
|Latest market close||$0.92|
|52-week range||$0.80 - $2.28|
|50-day moving average||$1.07|
|200-day moving average||$1.23|
|Wall St. target price||$3.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.22|
Buy Lipocine shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Lipocine stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Lipocine price performance over time
|1 week (2022-01-21)||2.69%|
|1 month (2021-12-24)||N/A|
|3 months (2021-10-28)||-10.28%|
|6 months (2021-07-28)||-31.71%|
|1 year (2021-01-28)||-49.44%|
|2 years (2020-01-28)||99.76%|
|3 years (2019-01-28)||1.61|
|5 years (2017-01-27)||3.64|
|Gross profit TTM||$-5,053,695|
|Return on assets TTM||-27.71%|
|Return on equity TTM||-75.11%|
|Market capitalisation||$77.2 million|
TTM: trailing 12 months
Lipocine share dividends
We're not expecting Lipocine to pay a dividend over the next 12 months.
Have Lipocine's shares ever split?
Lipocine's shares were split on a 1:100 basis on 24 July 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lipocine shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Lipocine shares which in turn could have impacted Lipocine's share price.
Lipocine share price volatility
Over the last 12 months, Lipocine's shares have ranged in value from as little as $0.8032 up to $2.28. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lipocine's is 0.3305. This would suggest that Lipocine's shares are less volatile than average (for this exchange).
Lipocine Inc. , a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH); TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
Lipocine in the news
Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO®
Lipocine : Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO® - Form 8-K
LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
Frequently asked questionsWhat percentage of Lipocine is owned by insiders or institutions?
Currently 2.534% of Lipocine shares are held by insiders and 10.471% by institutions. How many people work for Lipocine?
Latest data suggests 13 work at Lipocine. When does the fiscal year end for Lipocine?
Lipocine's fiscal year ends in December. Where is Lipocine based?
Lipocine's address is: 675 Arapeen Drive, Salt Lake City, UT, United States, 84108 What is Lipocine's ISIN number?
Lipocine's international securities identification number is: US53630X1046 What is Lipocine's CUSIP number?
Lipocine's Committee on Uniform Securities Identification Procedures number is: 53630X104
More guides on Finder
Cathie Wood’s ARK analysts predict Bitcoin at $1 million each by 2030
Five major factors contribute to the continued bull run of Bitcoin, ARK says, including growing adoption and long-term focus of investors.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Stocks are dropping; 3 rules for buying on the dip
Downturns often let you buy fundamentally strong stocks at bargain prices, but mind the fundamentals and consider these 3 rules.
The crypto market has lost $1.5 trillion in value — time to buy?
The crypto market wiped out $1.5 trillion in value in just three months.
Bitcoin tumbles past $40,000, altcoins follow
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s Pavia plot sale shows land rush is on in the metaverse
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Melania Trump has an NFT — what to know before you buy
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
Today’s top U.S. stocks: Mechel Pao ADRs (MTL ↑8.1%), Sibanye-Stillwater Limited (SBSW ↑7.4%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
How to order free at-home COVID tests today — but note, there’s a wait
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
Ask an Expert